Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Nephritis | 7 | 2025 | 85 | 1.900 |
Why?
|
| Lupus Erythematosus, Systemic | 8 | 2026 | 244 | 1.490 |
Why?
|
| Rheumatology | 3 | 2026 | 47 | 1.130 |
Why?
|
| Nephritis, Interstitial | 3 | 2020 | 44 | 0.740 |
Why?
|
| Autoantibodies | 6 | 2021 | 286 | 0.530 |
Why?
|
| Kidney | 7 | 2025 | 1121 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 212 | 0.450 |
Why?
|
| Lymphocytes | 1 | 2016 | 461 | 0.420 |
Why?
|
| Internship and Residency | 1 | 2023 | 1121 | 0.400 |
Why?
|
| Antibodies, Antinuclear | 2 | 2021 | 94 | 0.390 |
Why?
|
| Inflammation | 6 | 2025 | 1122 | 0.370 |
Why?
|
| Interferon-alpha | 2 | 2012 | 191 | 0.370 |
Why?
|
| Apoptosis | 1 | 2016 | 1752 | 0.310 |
Why?
|
| Vimentin | 2 | 2020 | 47 | 0.260 |
Why?
|
| Holistic Health | 1 | 2026 | 10 | 0.230 |
Why?
|
| Integrative Medicine | 1 | 2026 | 12 | 0.230 |
Why?
|
| Graft Rejection | 3 | 2025 | 1186 | 0.220 |
Why?
|
| Complementary Therapies | 1 | 2026 | 58 | 0.220 |
Why?
|
| Kidney Transplantation | 3 | 2025 | 939 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2012 | 2555 | 0.200 |
Why?
|
| Faculty | 1 | 2023 | 40 | 0.190 |
Why?
|
| Palatine Tonsil | 2 | 2021 | 34 | 0.170 |
Why?
|
| Allografts | 1 | 2021 | 220 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2023 | 969 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2021 | 132 | 0.150 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 727 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 449 | 0.140 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 285 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2025 | 1331 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 1 | 2022 | 445 | 0.130 |
Why?
|
| Humans | 16 | 2026 | 97979 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2023 | 864 | 0.130 |
Why?
|
| Mice, Inbred NZB | 1 | 2016 | 13 | 0.130 |
Why?
|
| Laser Capture Microdissection | 1 | 2016 | 20 | 0.120 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2016 | 25 | 0.120 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2016 | 44 | 0.120 |
Why?
|
| Antigen-Antibody Complex | 1 | 2016 | 89 | 0.120 |
Why?
|
| Germinal Center | 1 | 2016 | 66 | 0.120 |
Why?
|
| Kidney Glomerulus | 1 | 2016 | 121 | 0.120 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2016 | 112 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1815 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 435 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 193 | 0.110 |
Why?
|
| Interferons | 1 | 2015 | 114 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 894 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2016 | 351 | 0.100 |
Why?
|
| Inflammasomes | 1 | 2014 | 38 | 0.100 |
Why?
|
| Autoantigens | 1 | 2014 | 145 | 0.100 |
Why?
|
| Ohio | 1 | 2012 | 43 | 0.090 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 76 | 0.090 |
Why?
|
| Ribonucleoproteins | 1 | 2012 | 40 | 0.090 |
Why?
|
| Mycophenolic Acid | 2 | 2024 | 88 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 170 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2014 | 312 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2014 | 667 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 259 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 1302 | 0.080 |
Why?
|
| Female | 6 | 2025 | 51533 | 0.070 |
Why?
|
| Mice | 2 | 2021 | 12702 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1565 | 0.060 |
Why?
|
| Middle Aged | 4 | 2025 | 29388 | 0.060 |
Why?
|
| Animals | 5 | 2021 | 28907 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 2051 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2026 | 152 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2558 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2014 | 3623 | 0.050 |
Why?
|
| Male | 5 | 2025 | 47043 | 0.050 |
Why?
|
| Gene Ontology | 1 | 2021 | 38 | 0.040 |
Why?
|
| Adult | 4 | 2025 | 29496 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2021 | 174 | 0.040 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2020 | 33 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2021 | 213 | 0.040 |
Why?
|
| Rituximab | 1 | 2020 | 135 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2020 | 233 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 480 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 219 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2021 | 1027 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 1013 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 179 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2021 | 418 | 0.030 |
Why?
|
| Young Adult | 2 | 2024 | 7529 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 642 | 0.030 |
Why?
|
| Adolescent | 2 | 2024 | 10096 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2015 | 1850 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 139 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2014 | 76 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 188 | 0.030 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2014 | 31 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 373 | 0.030 |
Why?
|
| Monocytes | 1 | 2015 | 219 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 21737 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 164 | 0.020 |
Why?
|
| Morphine | 1 | 1994 | 127 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2019 | 0.020 |
Why?
|
| Naltrexone | 1 | 1994 | 139 | 0.020 |
Why?
|
| Prognosis | 1 | 2020 | 4115 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 505 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 358 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2012 | 195 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1320 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 1224 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 700 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 9688 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1995 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1994 | 470 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 7398 | 0.020 |
Why?
|
| United States | 1 | 2022 | 8220 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 2008 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 2482 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 10964 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 2638 | 0.010 |
Why?
|
| Drug Implants | 1 | 1994 | 36 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1994 | 59 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1994 | 55 | 0.010 |
Why?
|
| Body Temperature | 1 | 1994 | 127 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1994 | 239 | 0.010 |
Why?
|
| Analgesia | 1 | 1994 | 65 | 0.010 |
Why?
|
| Weight Loss | 1 | 1994 | 245 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 1255 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1994 | 1946 | 0.000 |
Why?
|
| Rats | 1 | 1994 | 4070 | 0.000 |
Why?
|
| Time Factors | 1 | 1994 | 5561 | 0.000 |
Why?
|